mRNA vaccine technology is a transformative new sector of the biopharmaceutical industry which has revolutionized vaccine development through increased speed, safety and cost-effective development leading to the first approved vaccines for the COVID-19 pandemic.
mRNA technology allows researchers to fast-track the early stages of vaccine research and development and to produce vaccines faster and more efficiently.
How does an mRNA Vaccine work?
mRNA (messenger RNA) instructs the body to produce proteins which can treat or prevent disease or infections. mRNA vaccines are mRNA molecules that are packaged (encapsulated) in lipid nanoparticles and delivered directly into cells to make proteins to treat or prevent disease or infections by pathogens such as SARS-CoV-2 and emerging “Variants of Concern”.
Fundamental biology of life
DNA (deoxyribonucleic acid) is a double-stranded molecule that stores the genetic instructions for all life on earth. DNA enables the body’s cells to make proteins via RNA (ribonucleic acid) which is derived naturally from DNA. Nearly every function in the body – both normal and disease-related – is a result of one or more proteins.
mRNA enables expression of DNA into proteins
mRNA enables the genetic code of DNA to be used naturally in a process known as protein synthesis. mRNA is the single-stranded molecule that carries genetic code from DNA in a cell’s nucleus to the ribosome, which is the center of protein synthesis in the cell.
How mRNA enables protein synthesis
A copy of a DNA sequence is generated naturally into mRNA. The mRNA migrates from the nucleus of the cell to the cytoplasm, which houses ribosomes.
Nature’s factory in the cell that is responsible for making proteins from mRNA.
The ribosome translates the mRNA into a protein with amino acids which are the building blocks of protein.
The expressed protein functions in the cell or the body, naturally.
Our mission is to enable the large-scale production of highly affordable mRNA vaccines for the people and with a great return on investment for the potential investors. Our goal is to mass-produce mRNA vaccines and to market them for $4 per dose on Advance Purchase Agreements (APA).
Phase 1 Vaccines
Phase 2 Vaccines
During Phase 2, Normax plans to develop a new mRNA Vaccine in 100 Days and to build Vax Factories for mRNA Cancer Vaccines in up to 100 Locations. Our goal is to reach a production capacity of 300 million doses per month, on a widely distributed network of Vax Factories.
Our long-term goal is to end the transmission of TB and HIV by 2050.